Published in Vaccine on December 20, 2012
HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles. J Acquir Immune Defic Syndr (2015) 0.87
Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses (2014) 0.81
Group M consensus Gag and Nef peptides are as efficient at detecting clade A1 and D cross-subtype T-cell functions as subtype-specific consensus peptides. Vaccine (2014) 0.75
Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene. PLoS One (2016) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 4.07
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One (2012) 2.97
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med (2012) 2.40
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS (2006) 1.98
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr (2015) 1.73
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS (2007) 1.73
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med (2012) 1.63
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr (2012) 1.53
Breast cancer in a cohort of human immunodeficiency virus (HIV)-infected women from Rio de Janeiro, Brazil: a cases series report and an incidence rate estimate. Braz J Infect Dis (2011) 1.44
The DART trial: 'The doctor's dilemma' revisited. J Antimicrob Chemother (2011) 1.42
Phylogeography and evolutionary history of dengue virus type 3. Infect Genet Evol (2008) 1.37
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care (2010) 1.30
Epidemiology of HIV in Latin America and the Caribbean. Curr Opin HIV AIDS (2014) 1.24
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS (2011) 1.19
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr (2010) 1.17
Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003. AIDS (2005) 1.16
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther (2009) 1.15
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS (2010) 1.15
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr (2007) 1.12
Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates. Retrovirology (2009) 1.11
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis (2013) 1.11
HIV-1 genetic diversity and drug resistance among treatment naïve patients from Southern Brazil: an association of HIV-1 subtypes with exposure categories. J Clin Virol (2011) 1.10
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther (2010) 1.10
Overcoming biological, behavioral, and structural vulnerabilities: new directions in research to decrease HIV transmission in men who have sex with men. J Acquir Immune Defic Syndr (2013) 1.07
Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr (2009) 1.06
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses (2011) 1.06
Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr (2007) 1.05
Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore. J Acquir Immune Defic Syndr (2011) 1.04
Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: influence of HIV-1 coinfection. Diagn Mol Pathol (2005) 1.04
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS (2012) 1.03
Diagnostic detection of human immunodeficiency virus type 1 antibodies in urine: a brazilian study. J Clin Microbiol (2002) 1.01
Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant Couples. J Acquir Immune Defic Syndr (2015) 1.01
Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses (2010) 1.01
Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women. Int J Infect Dis (2008) 1.01
HIV testing among pregnant women in Brazil: rates and predictors. Rev Saude Publica (2008) 1.00
Longitudinal analysis of HIV-1 BF1 recombinant strains in vertically infected children from Argentina reveals a decrease in CRF12_BF pol gene mosaic patterns and high diversity of BF unique recombinant forms. Infect Genet Evol (2010) 1.00
Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life. Braz J Infect Dis (2013) 0.98
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis (2004) 0.97
Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials (2010) 0.96
Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study. BMC Infect Dis (2009) 0.96
Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil. BMC Infect Dis (2010) 0.96
Acceptability of self-conducted home-based HIV testing among men who have sex with men in Brazil: data from an on-line survey. Cad Saude Publica (2014) 0.95
Description of the first full-length HIV type 1 subtype F1 strain in Argentina: implications for the origin and dispersion of this subtype in South America. AIDS Res Hum Retroviruses (2007) 0.95
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 0.95
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol (2014) 0.95
High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load. BMC Infect Dis (2010) 0.95
Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART. PLoS One (2012) 0.94
Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS (2006) 0.93
HIV-1 seroprevalence in the general population of Salvador, Bahia State, Northeast Brazil. Cad Saude Publica (2007) 0.93
Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr (2009) 0.93
Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J Med Virol (2009) 0.92
Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011. BMC Infect Dis (2014) 0.92
Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr (2009) 0.91
Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection. J Infect Dis (2013) 0.91
Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country. Int J Cancer (2011) 0.91
Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS One (2010) 0.91
Anal human papillomavirus (HPV) prevalences and factors associated with abnormal anal cytology in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil. AIDS Patient Care STDS (2015) 0.90
Using conjoint analysis to measure the acceptability of rectal microbicides among men who have sex with men in four South American cities. AIDS Behav (2012) 0.90
Phylodynamics of HIV-1 subtype C epidemic in east Africa. PLoS One (2012) 0.90
Cell-cycle and suppressor proteins expression in uterine cervix in HIV/HPV co-infection: comparative study by tissue micro-array (TMA). BMC Cancer (2008) 0.90
Phylodynamics of the HIV-1 epidemic in Cuba. PLoS One (2013) 0.89
High frequency of recombinant genomes in HIV type 1 samples from Brazilian southeastern and southern regions. AIDS Res Hum Retroviruses (2002) 0.89
Increasing heterosexual transmission of HIV-1 subtype C in Inland Central Western Brazil. J Med Virol (2012) 0.89
Near full-length genome characterization of HIV type 1 unique BC recombinant forms from Southern Brazil. AIDS Res Hum Retroviruses (2009) 0.88
Temporal dynamics of HIV-1 circulating subtypes in distinct exposure categories in southern Brazil. Virol J (2012) 0.88
Epidemic history of Hepatitis C virus in Brazil. Infect Genet Evol (2010) 0.88
Factors associated with colposcopy-histopathology confirmed cervical intraepithelial neoplasia among HIV-infected women from Rio De Janeiro, Brazil. PLoS One (2011) 0.87
Genetic characterization of HIV-1 BC recombinants and evolutionary history of the CRF31_BC in Southern Brazil. Infect Genet Evol (2009) 0.87
Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study. Pediatr Infect Dis J (2015) 0.87
Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil. J Acquir Immune Defic Syndr (2011) 0.87
Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Hepatol Res (2008) 0.87
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr (2017) 0.87
Behavior surveillance: prevalence and factors associated with high-risk sexual behavior among HIV-infected men in Brazil in the post-HAART era. AIDS Behav (2008) 0.86
HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil. Rev Saude Publica (2010) 0.86
HIV-1 infection among injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incidence and genetic diversity. J Clin Virol (2004) 0.86
Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother (2014) 0.85
Distribution of CCR5 genotypes and HLA Class I B alleles in HIV-1 infected and uninfected injecting drug users from Rio de Janeiro, Brazil. Infect Genet Evol (2009) 0.85
HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola. PLoS One (2012) 0.85
Participation of women in HIV clinical trials: the IPEC-FIOCRUZ experience. HIV AIDS (Auckl) (2011) 0.85